New from
#AACR26: A small clinical trial (8-person) at MSK is showing promise for people with early-stage
#rectalcancer whose tumors are driven by excessive amounts of a protein called HER2 (human epidermal growth factor receptor 2).
The trial, led by MSK gastrointestinal medical oncologists Dr.
@MikeFooteMD and Dr.
@AndreaCercek, suggests that many of these patients may be successfully treated using targeted therapies to avoid surgery, resulting in fewer side effects and better quality of life during and after treatment.
Learn more about this research:
bit.ly/4tiSVvL @aacr